No profile data available.
Sera Prognostics, Inc. (SERA) is a healthcare company in the DNA testing equipment industry, based in Salt Lake City, United States, with about 71 full-time employees.
It reported revenue of $81,000 for fiscal year 2025, up 5.2% from fiscal year 2024, and net income of -$31.93 million. Its market capitalization was $80.48 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Sera Prognostics reported $81,000 in revenue for fiscal year 2025, up 5.2% from $77,000 in fiscal year 2024.
$80.48 million as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Myriad Genetics, Inc. (MYGN), Burning Rock Biotech Limited (BNR), Cardiff Oncology, Inc. (CRDF), MDxHealth SA (MDXH).